Oclacitinib

Oclacitinib is a novel JAK inhibitor. Oclacitinib is most potent at inhibiting JAK1 (IC50=10 nM) .

Product Specifications

CAS Number

[1208319-26-9]

Product Name Alternative

PF-03394197

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

JAK

Type

Reference compound

Related Pathways

Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/Oclacitinib.html

Concentration

10mM

Purity

99.59

Solubility

DMSO : 5 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

CN([C@H]1CC[C@@H](CC1)CS(NC)(=O)=O)C2=C3C(NC=C3)=NC=N2

Molecular Formula

C15H23N5O2S

Molecular Weight

337.44

Precautions

H302, H315, H319, H335

References & Citations

[1]Gonzales AJ, et al. Oclacitinib (APOQUEL) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy. J Vet Pharmacol Ther. 2014 Aug;37 (4) :317-24.|[2]Fukuyama T, et al. Topically Administered Janus-Kinase Inhibitors Tofacitinib and Oclacitinib Display Impressive Antipruritic and Anti-Inflammatory Responses in a Model of Allergic Dermatitis. J Pharmacol Exp Ther. 2015 Sep;354 (3) :394-405.|[3]Cosgrove SB, et al. Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis. Vet Dermatol. 2013 Oct;24 (5) :479-e114.